MTOR and metastatic neoplasm: Consequently, the National Comprehensive Cancer Network (NCCN) guidelines recommend albumin-bound sirolimus for unresectable locally advanced disease or metastatic disease; the intravenous administration of nanoparticle protein-bound sirolimus showed higher intratumoral accumulation, mTOR inhibition, and tumor growth inhibition compared to oral mTOR inhibitors (67, 68).